RxDoctor Payments Data

Jonathan Schoenfeld, MD

Radiation Oncology · Boston, MANPI 1295994978

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $38,988 of the $53,313 with a category attached, or 73.1%. 7 manufacturers reported payments, led by Merck Kgaa at 50.8% of the total. Reporting peaked in 2024 at $24,838 and has fallen 98.9% since, to $271 in 2025. Among radiation oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,313in general payments, 2019–2025

Across 25 payments — averaging $2132.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck Kgaa$27K
  • EMD Serono, Inc.$21K
  • Genentech, Inc.$3K
  • EMD Serono Research & Development Institute, Inc.$2K
  • Regeneron$259
  • Lantheus Medical Imaging, Inc.$239
  • plus $33 from 1 others
$1,611,378in research payments, 2019–2025

Across 33 payments — averaging $48,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$1.5M
  • EMD Serono, Inc.$124K
  • Merck Healthcare Kgaa$30K
  • Regeneron$747
  • Merck Kgaa$690

What the payments were for

  • Consulting fees$38,98873%
  • Speaking & faculty fees$13,12025%
  • Food & beverage$1,2052%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,313 in reported general payments places this provider in the 95th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$85,631
Medicare patients
145
Services billed
954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate20$300

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →